Clinical Cancer Genomics conference, March 20-21 2025, Amsterdam
We are pleased to announce that registration for this novel exciting meeting focused on cancer whole genome and transcriptome sequencing in a clinical setting, is now open. Please visit www.ccg2025.eu for more information, abstract submission or registration of your participation!
An increasing number of European countries are adapting clinical cancer (gen)omics programs including whole genome and transcriptome sequencing (WGTS) to enable cancer precision medicine and support research and a learning health care system for improving future cancer care.
This meeting will be the first of an annual recurring series and aims to bring together researchers and medical specialists involved in these programs or interested in genomics-based and data-driven cancer care and/or research. The current state-of-the-art implementations in routine care, research highlights, clinical impact and future developments will be presented and discussed.
National programs in Europe supporting translation of genomics approaches from the clinic to research and back will be central to this meeting. The first meeting will take place on Thursday March 20 and Friday 21, 2025 in Amsterdam, the Netherlands, and is initiated as part of the 10th anniversary of Hartwig Medical Foundation. The meeting will be organised together with Genomics England, DKFZ German Cancer Research Center MASTER/NCT, Genomic Medicine Sweden, Plan France Médecine Génomique 2025 , and Danish National Genome Center.
All news
Also read
Hartwig advances precision oncology worldwide with oncoanalyser
Nicole Schonrock on scaling precision care for patients with cancer in Australia Hartwig Medical Foundation has developed powerful software for …
Hartwig and Ultima Expand Collaboration to Advance WGS in Oncology Care
Hartwig and Ultima strengthen collaboration on whole‑genome sequencing Hartwig Medical Foundation to adopt Ultima Genomics’ UG200 sequencing system to accelerate …
Comprehensive molecular diagnostics closer for more patients thanks to price reduction
Hartwig Medical Foundation reduces the price of its OncoAct Whole Genome Sequencing (WGS) service as of January 1, 2026. This …
A complete genetic analysis should be part of the standard diagnostics for every patient with cancer who is eligible for treatment. WGS contributes to better, coordinated treatment advice. In this way, we reduce over- and under-treatment, while making healthcare more cost-effective and keeping it affordable.